Association between EV or plasma TF activity and VTE and mortality in cancer patients
| Reference . | Tumor type . | No. of patients with VTE/total no. of patients . | % . | Assay . | VTE . | Mortality . |
|---|---|---|---|---|---|---|
| 19 | Pancreatic | 5/23 | 22 | EVTF activity | Higher EVTF activity in patients with VTE vs patients without VTE* | ↑EVTF activity associated with mortality |
| Breast | 2/27 | 7 | ||||
| 24 | Pancreatic | 2/10 | 20 | EVTF activity | 2 patients with serial increases in EVTF activity had VTE | ND |
| 20 | Pancreatic | 12/60 | 20 | EVTF activity | Hazard ratio (per doubling of EVTF activity) pancreatic, 1.6; stomach, 0.7; brain, 0.9. All nonsignificant (borderline for pancreatic). | ↑EVTF activity associated with mortality in pancreatic cancer but not in other cancers |
| Stomach | 6/43 | 14 | ||||
| Colorectal | 12/126 | 9 | ||||
| Brain | 19/119 | 16 | ||||
| 21 | Pancreatic and biliary† | 52/117 | 45 | EVTF activity | ↑EVTF activity in patients (3.07 ± 5.2) with VTE vs patients without (1.4 ± 1.5) (P = .01) | ↑EVTF activity associated with mortality |
| 23 | 17 different types of cancers | 11/60 | 11 | EVTF activity | EVTF activity was not associated with VTE. | ↑EVTF activity associated with mortality |
| 22 | 9 different types of cancers | 40/648 | 6.1 | TF-dependent fibrin generation | ↑Fibrin generation associated with VTE. | ND |
| NP | Pancreatic | 1/13 | 8 | EVTF activity | 1 pancreatic cancer patient with ↑EVTF activity had VTE | 2 pancreatic cancer patients with ↑EVTF activity died |
| Colorectal‡ | 5/22 | 23 |
| Reference . | Tumor type . | No. of patients with VTE/total no. of patients . | % . | Assay . | VTE . | Mortality . |
|---|---|---|---|---|---|---|
| 19 | Pancreatic | 5/23 | 22 | EVTF activity | Higher EVTF activity in patients with VTE vs patients without VTE* | ↑EVTF activity associated with mortality |
| Breast | 2/27 | 7 | ||||
| 24 | Pancreatic | 2/10 | 20 | EVTF activity | 2 patients with serial increases in EVTF activity had VTE | ND |
| 20 | Pancreatic | 12/60 | 20 | EVTF activity | Hazard ratio (per doubling of EVTF activity) pancreatic, 1.6; stomach, 0.7; brain, 0.9. All nonsignificant (borderline for pancreatic). | ↑EVTF activity associated with mortality in pancreatic cancer but not in other cancers |
| Stomach | 6/43 | 14 | ||||
| Colorectal | 12/126 | 9 | ||||
| Brain | 19/119 | 16 | ||||
| 21 | Pancreatic and biliary† | 52/117 | 45 | EVTF activity | ↑EVTF activity in patients (3.07 ± 5.2) with VTE vs patients without (1.4 ± 1.5) (P = .01) | ↑EVTF activity associated with mortality |
| 23 | 17 different types of cancers | 11/60 | 11 | EVTF activity | EVTF activity was not associated with VTE. | ↑EVTF activity associated with mortality |
| 22 | 9 different types of cancers | 40/648 | 6.1 | TF-dependent fibrin generation | ↑Fibrin generation associated with VTE. | ND |
| NP | Pancreatic | 1/13 | 8 | EVTF activity | 1 pancreatic cancer patient with ↑EVTF activity had VTE | 2 pancreatic cancer patients with ↑EVTF activity died |
| Colorectal‡ | 5/22 | 23 |